IMPROVED TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TREATMENT OF PARKINSON'S DISEASE.

摘要

The use of a silicone-based transdermal therapeutic system comprising a mixture of at least one high adhesion silicone adhesive and at least one medium adhesion as the main adhesive components having an area of 10 to 40 cm2 and containing 0, 1 to 3, 15 mg / cm2 of rotigotine in the form of free base as an active ingredient, for the preparation of an anti-Parkinson's drug that achieves improvement, compared to placebo treatment, in the condition of a Parkinson's patient human, measured according to the Unified Evaluation Scale for Parkinson's Disease (UPDRS) II and III, of 2 or more units after administration for at least 7 weeks.